Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorect...

Dr Akihito Kawazoe speaks to ecancer about the LEAP-017 study he presented at WCGIC 2023 evaluating lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer.

He explains that in the phase II lenvatinib plus pembrolizumab had promising anti tumour activity with manageable safety profiles.

Dr Kawazoe reports that overall survival was 9.8 months for lenvatinib plus pembrolizumab vs 9.3 months with standard of care although this did not meet the threshold for statistical significance.

• Categoria